Summary & Overview
HCPCS J1302: Injection, sutimlimab-jome, 10 mg
HCPCS Level II code J1302 denotes the injection product sutimlimab-jome, reported in 10 mg units, and applies to outpatient pharmacologic infusion or injection services. This biologic therapy is relevant nationally for providers, payers, and billing teams because accurate coding affects medical record clarity, payer adjudication, and patient access to specialty therapies. Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find an overview of the code's clinical context and typical service setting, plus operational benchmarks and policy considerations affecting coverage and billing workflows. The publication summarizes payer coverage patterns, common billing practices, and relevant claim edit considerations for reporting biologic injections in outpatient settings. Where input data is incomplete, the report identifies gaps and lists items marked as "Data not available in the input." The goal is to provide concise, nationally focused information to inform revenue cycle, clinical administration, and payer contracting discussions around reporting and processing of J1302.
Billing Code Overview
HCPCS Level II code J1302 represents Injection, sutimlimab-jome, 10 mg. This code is used to report administration of the monoclonal antibody product sutimlimab-jome in 10 mg units. The service type for this code is pharmacologic injection/infusion therapy, and the typical site of service is outpatient infusion centers or clinic-based infusion suites where parenteral biologic therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient for J1302 is an adult with cold agglutinin disease (CAD) or another CAD-spectrum complement-mediated hemolytic anemia being treated with intravenous sutimlimab-jome. The clinical workflow begins with a hematology visit to assess hemolysis markers (hemoglobin, bilirubin, lactate dehydrogenase, haptoglobin) and symptom burden (fatigue, transfusion dependence, cold-induced circulatory symptoms). After eligibility is confirmed and consent obtained, the patient arrives at an infusion center or hospital outpatient infusion suite. Baseline vital signs and pre-medication (if indicated) are given. The medication is prepared by pharmacy as sutimlimab-jome in the appropriate concentration; billing uses J1302 per 10 mg increment. The infusion is administered intravenously by an RN with monitoring for infusion reactions; vitals are recorded at regular intervals. Post-infusion observation ensures stability before discharge. Documentation includes indication, dose (total mg and units of J1302 billed), lot numbers, administration route, start/stop times, pre/post vitals, and any reactions or interventions. Typical sites of service include outpatient infusion centers, hospital outpatient departments, and oncology/hematology clinics with infusion capability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug wasted (discarded) | Use when part of the single-use vial is discarded and payer requires reporting of discarded medication. |
JZ | No drug was wasted | Use when the exact supplied drug amount was fully administered with no waste. |
52 | Reduced services | Use if the planned infusion was partially performed (e.g., early discontinuation with clinical rationale) and documentation supports reduced service. |
53 | Discontinued procedure (safeguard) | Use when infusion is started but then discontinued due to patient instability or adverse event. |
59 | Distinct procedural service (not in provided list) | Data not available in the input. |
22 | Increased procedural services | Use when administration required substantially greater resources (complex access, extended monitoring) and documentation supports unusual effort. |
76 | Repeat procedure by same provider (not in provided list) | Data not available in the input. |
78 | Return to OR for related procedure (not typical) | Rarely used; generally not applicable to infusion services but included in raw modifiers list for completeness when a surgical return is relevant. |
80 | Assistant surgeon (not applicable) | Typically not applicable to J1302 infusions; included when surgical assistance is billed. |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services payable under Medicare Part B (surgical assist) | Rare for infusion administration; may be used when advanced practitioner documents primary procedural role per payer rules. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RH0000X | Hematology | Hematologists prescribe and manage sutimlimab therapy and monitor response. |
207RG0300X | Medical Oncology | Oncologists manage complex infusion therapies when CAD care is delivered in oncology clinics. |
363A00000X | Infusion Therapy | Infusion nurses and centers provide administration and monitoring. |
3336C0002X | Clinical Pharmacology | Pharmacists oversee drug preparation, dosing, and stability notes. |
364S00000X | Registered Nurse | RNs perform the infusion, monitoring, and documentation. |
Note: Modifier selection must be supported by contemporaneous clinical documentation and local payer rules. The raw modifier list included many codes; the table focuses on those most often pertinent to IV biologic infusions like J1302.
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
D59.1 | Cold agglutinin hemolytic anemia | Primary indication for sutimlimab-jome; targets complement-mediated hemolysis in cold agglutinin disease. |
D59.0 | Drug-induced hemolytic anemia | Differential diagnosis; relevant when hemolysis may be medication-mediated and treatment decisions consider immune etiology. |
D59.9 | Hemolytic anemia, unspecified | Used when hemolytic process is documented but specific cause not yet determined; supports use of targeted therapies after workup. |
D50.9 | Iron deficiency anemia, unspecified | Common comorbid anemia; important to distinguish from hemolytic causes as management differs. |
D64.9 | Anemia, unspecified | General anemia diagnosis that may coexist; used when coding lacks specificity but therapy monitoring continues. |
R71.8 | Other abnormality of red blood cells | Lab abnormality code used for hemolysis-related findings supporting treatment decisions. |
Z51.11 | Encounter for antineoplastic chemotherapy | Used if infusion center billing conventions map biologic infusion visit to chemotherapy encounter scheduling and resource use. |
Z79.899 | Other long term (current) drug therapy | Used to indicate chronic biologic therapy when appropriate per payer guidance. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96413 | Chemotherapy administration, IV infusion, for non-hormonal anti-neoplastic; each additional hour (List separately in addition to primary code) | Used for extended infusion time billing when infusion duration exceeds the base administration time and payer allows when sutimlimab-jome administration parallels infusion oncology timing conventions. |
96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | Commonly billed for the initial hour of a therapeutic IV infusion in outpatient infusion centers when payers accept this code for biologic administrations. |
96366 | Intravenous infusion, each additional hour | Billed for additional hours beyond the initial infusion hour when clinically required and documented. |
36415 | Collection of venous blood by venipuncture | Performed for baseline and follow-up laboratory monitoring related to treatment with sutimlimab-jome. |
99058 | Services provided during extended office hours | Used selectively by some practices when infusion services occur outside regular hours per payer policy. |
96379 | Unlisted therapeutic, prophylactic, or diagnostic IV infusion or injection (use only if no appropriate code) | Rarely used; only when a specific administration scenario falls outside established administration CPT codes and documentation supports use. |
If local payer rules differ, facilities map administration codes per payer guidance; coding must reflect actual service time, personnel, and documentation.